GleamWall
中文EN

NGNE Neurogene Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1404644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-40.0%
TTM EPS YoY-22.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.4%
ROA-35.8%
ROIC (approx.)-43.7%
Asset turnover—

Leverage & solvency

Liabilities / assets6.1%
Debt / equity0.00x
Current ratio19.97x
Interest coverage-129,924.00x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$925,000
R&D expense$75.01M$60.92M
SG&A expense$28.32M$22.61M
Operating income-$103.33M-$82.61M
Interest expense$5,000$12,000
Pretax income-$90.35M-$75.14M
Income tax$0$0
Net income-$90.35M-$75.14M
EBITDA-$100.28M-$79.41M
EPS (basic)-4.24-4.28
EPS (diluted)-4.24-4.28
Weighted avg. shares (diluted)21.33M17.57M
Balance sheet
Cash & equivalents$103.84M$136.93M
Short-term investments$165.17M$175.82M
Current assets$271.77M$315.92M
PP&E, net$12.79M$15.42M
Total assets$288.60M$335.73M
Current liabilities$16.41M$15.16M
Total liabilities$23.72M$25.36M
Shareholders' equity$264.89M$310.38M
Shares outstanding15.49M14.85M
Cash flow statement
Operating cash flow-$77.17M-$70.60M
Capital expenditure$1.18M$808,000
Free cash flow-$78.36M-$71.41M
Investing cash flow$14.00M-$125.26M
Financing cash flow$30.43M$184.07M
Depreciation & amortization$3.04M$3.19M
Stock-based compensation$14.18M$8.32M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.